These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26339737)

  • 1. Letter to the Editor: Liraglutide-Induced Increase in Bone Formation Can Be Dependent on Osteocalcin.
    Kizilgul M; Kan S; Beysel S; Delibasi T
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L71. PubMed ID: 26339737
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women" by Iepsen E.W., et al.
    Conte C; Cecere A; Guglielmi G; Napoli N
    J Clin Endocrinol Metab; 2015 Oct; 100(10):L92-3. PubMed ID: 26439158
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to the Letter by Napoli N., et al.
    Iepsen EW
    J Clin Endocrinol Metab; 2015 Oct; 100(10):L94-5. PubMed ID: 26439159
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to the Letter by Kizilgul M., et al.
    Iepsen EW
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L72. PubMed ID: 26339738
    [No Abstract]   [Full Text] [Related]  

  • 5. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 8. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 9. Liraglutide for weight loss in obese people.
    Thum T; Anker SD
    Lancet; 2010 Feb; 375(9714):551-2; author reply 552-3. PubMed ID: 20159285
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1R agonists are not a quick fix for weight loss.
    Iverson KA
    BMJ; 2012 Feb; 344():e1455; author reply e1459. PubMed ID: 22374905
    [No Abstract]   [Full Text] [Related]  

  • 12. [GLP-1 agonist supports weight loss].
    Weiß M
    MMW Fortschr Med; 2016 Feb; 158(2):71. PubMed ID: 26961053
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility of GLP-1R agonists in diabetes requires long term study.
    de Oliveira JM
    BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904
    [No Abstract]   [Full Text] [Related]  

  • 14. Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.
    Dear AE
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):363-4. PubMed ID: 23722420
    [No Abstract]   [Full Text] [Related]  

  • 15. Liraglutide for weight loss in obese people.
    Hallberg P; Schwan S; Melhus H
    Lancet; 2010 Feb; 375(9714):551; author reply 552-3. PubMed ID: 20159284
    [No Abstract]   [Full Text] [Related]  

  • 16. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal hormones and weight management.
    Bray GA
    Lancet; 2009 Nov; 374(9701):1570-1. PubMed ID: 19853907
    [No Abstract]   [Full Text] [Related]  

  • 18. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
    Ruby RJ; Armato JP; Pyke C; Peters AL
    Diabetes Care; 2014 Aug; 37(8):e177-8. PubMed ID: 25061148
    [No Abstract]   [Full Text] [Related]  

  • 19. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.
    Dai Y; Mehta JL; Chen M
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):371-80. PubMed ID: 23657563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.